Director, Cardiac Catheterization Laboratory, Scripps Clinic/Green Hospital
Cardiology
Dr. Matthew J. Price, MD
|
|
Give Review
Doctor Matthew J. Price, MD is an expert in the field of Cardiology. He graduated from David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical college. David Geffen School of Medicine at UCLA has a rank of 13 in research and a 7 in primary care He has 1 awards "Fellow (FACC)". Dr. Matthew J. Price is also a published doctor. He has 67 paper published. The most recent paper is: Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Matthew Price is registered with Medicare and accepts Medicare payments.
Publications
- Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y1...
- Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous Coronary intervention: the GRAVITAS randomized trial.
- Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
- Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
- PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
- Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable Coronary disease: the recove...
- Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Stan...
- Update on the Guidelines for the Management of ST-Elevation Myocardial Infarction.
- Left Atrial appendage closure-facing the truth and forging the future.
- Left Main Percutaneous Coronary Intervention.
- A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable Coronary artery disease.
- Diabetes mellitus and clopidogrel response variability.
- Percutaneous closure of paravalvular leak after transcatheter Aortic valve replacement.
- Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREV...
- Platelet reactivity after Coronary stenting.
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events.
- Novel uses for platelet function testing in the clinical laboratory: where are we now?
- Cangrelor for treatment of arterial thrombosis.
- Detecting Thienopyridine Effect By Platelet Reactivity Assessment and Its Implications for Risk Stratification.
- Conversations in Cardiology: Bridging antiplatelet therapy before surgery.
- Bedside evaluation of thienopyridine antiplatelet therapy.
- Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial.
- Percutaneous management of late leak after lariat transcatheter ligation of the left Atrial appendage in patients with Atrial fibrillation at high risk for stroke.
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding.
- Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures.
- The role of clopidogrel in the management of ischemic Heart disease.
- Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring Coronary artery bypass surgery.
- Platelet function monitoring and clopidogrel.
- Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous Coronary intervention: the GIFT (Genotype Information and Fu...
- Left Atrial appendage occlusion for the reduction of stroke and embolism in patients with Atrial fibrillation.
- Platelet-Mediated Thrombosis and Drug-Eluting Stents.
- Impact of platelet reactivity on clinical outcomes after percutaneous Coronary intervention a collaborative meta-analysis of individual participant data.
- Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter.
- The brave new world of antiplatelet therapy: seeking clarity in a world of increasing choice and complexity.
- The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
- Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
- A novel technique for ultra-low contrast administration during angiography or intervention.
- The evidence base for platelet function testing in patients undergoing percutaneous Coronary intervention.
- Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.
- Utility of on-line three-dimensional transesophageal echocardiography during percutaneous Atrial septal defect closure.
- Three-year outcome of drug-eluting stent implantation for Coronary artery bifurcation lesions.
- Intraprocedural stent thrombosis during crush stenting of the left main Coronary artery bifurcation.
- Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization.
- Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous Coronary intervention.
- Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the ...
- Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
- Safety and performance of targeted renal therapy: the Be-RITe! Registry.
- Change we can believe in: the hyper-evolution of percutaneous Coronary intervention for unprotected left main disease with drug-eluting stents.
- The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-m...
- Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
- New antiplatelet therapies in development.
- A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main Coronary artery disease.
- Clopidogrel desensitization after drug-eluting stent placement.
- Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous Coronary intervention (the REMOVE trial).
- Utility of three-dimensional reconstruction of Coronary angiography to guide percutaneous Coronary intervention.
- IntraCoronary radiation therapy for multi-drug resistant in-stent restenosis: initial clinical experience.
- Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent Failure.
- Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
- Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization.
- A multicenter, randomized, dose-finding study of gamma intraCoronary radiation therapy to inhibit recurrent restenosis after stenting.
- Rescue percutaneous Coronary intervention early after Coronary artery bypass grafting in the drug-eluting stent era.
- Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main Coronary artery revascularization.
- IntraMyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of Myocardial...
- Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions.
- Stem cell repair of infarcted myocardium: an overview for clinicians.
- New strategies in managing and preventing Atherosclerosis: focus on HDL.
Schools
University Of California Los Angeles School Of Medicine
University Of California Los Angeles Center For Health Sciences
Cedars Sinai Medical Center
Scripps Clinic
Cornell University
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Angioplasty With Stent Placement
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Ectasia
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Enhanced Exclusive for Small Business HMO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- GEHA
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACC)
Education
-
Scripps Clinic -
Cedars-Sinai Medical Center -
UCLA Medical Center -
David Geffen School of Medicine at UCLA
Drug Facts
| NPI NUMBER | 1659343945 | |
| NPPES Provider LastName | PRICE | |
| NPPES Provider FirstName | MATTHEW | |
| NPPES Provider ZIPCode | 920371027 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 122.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659343945 |
| Last Name Of The Provider | PRICE |
| First Name Of The Provider | MATTHEW |
| View All |
Similar Doctors
|
|
Dr. Filip Fattohi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric J. Topol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas W. Triffon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ernest E. Pund Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold H. Shively Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malhar P. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merri M. McMahon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mitul P. Patel, MD |
|
|
Dr. Robert J. Russo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kirk L. Peterson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sotirios Tsimikas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Rogers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina L. Adams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanae Mukai, MD |
|
|
Linda M. Couts, NP
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alok Sharma, MD |